Medtronic bullish over doubts regarding drug-eluting stent plans
This article was originally published in Clinica
Executive Summary
Medtronic's goal of gaining US market approval for its first drug-eluting stent (DES) late next year has been thrown into doubt, following the release of 12-month follow-up data from a clinical trial of its DES, Endeavor.